Efficacy of mirtazapine in obstructive sleep apnea syndrome

Sleep

Volumn 30, Issue 1, 2007, Pages 35-41

  Carley, David W ^a   Olopade, Christopher ^a   Ruigt, Ge S ^b   Radulovacki, Miodrag ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NV ORGANON   (Netherlands)

Author keywords

Apnea; Clinical trial; Drug treatment; Mirtazapine; OSA; Placebo controlled; Randomized; Serotonin

Indexed keywords

MIRTAZAPINE; PLACEBO; SEROTONIN; SEROTONIN 2 ANTAGONIST; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SELF ADMINISTRATION; FEMALE; HUMAN; MALE; NONREM SLEEP; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REM SLEEP; SEDATION; SEROTONIN RELEASE; SIDE EFFECT; SLEEP APNEA SYNDROME; SLEEP WAKING CYCLE; WEIGHT GAIN;

EID: 33846227045     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: 10.1093/sleep/30.1.35     Document Type: Article

References (41)

1. Veasey SC. Pharmacotherapies for obstructive sleep apnea: how close are we? Curr Opin Pulm Med 2001;7:399-403.
2. Carley D, Radulovacki M, eds. Sleep-Related Breathing Disorders: Experimental Models and Therapeutic Potential. Vol. 171. New York: Marcel Dekker; 2003.
3. Sood S, Morrison JL, Liu H, Horner RL. Role of endogenous serotonin in modulating genioglossus muscle activity in awake and sleeping rats. Am J Respir Crit Care Med 2005;172:1338-47.
4. Fenik P, Veasey SC. Pharmacological characterization of serotonergic receptor activity in the hypoglossal nucleus. Am J Respir Crit Care Med 2003;167:563-9.
5. Veasey SC, Panckeri KA, Hoffman EA, Pack AI, Hendricks JC. The effects of serotonin antagonists in an animal model of sleep- disordered breathing. Am J Respir Crit Care Med 1996;153:776-86.
6. Veasey SC, Fenik P, Panckeri K, Pack AI, Hendricks JC. The effects of trazodone with L-tryptophan on sleep-disordered breathing in the English bulldog. Am J Respir Crit Care Med 1999;160:1659-67.
7. Schmidt H. L-tryptophan in the treatment of imparied respiration in sleep. Bull Eur Physiopathol Respir 1983;19:625-9.
8. Hanzel D, Proia N, Hudgel DW. Response of obstructive sleep apnea to fluoxetine and protriptyline. Chest 1991;100:416-21.
9. Kraiczi H, Hedner J, Dahlof P, Ejnell H, Carlson J. Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea. Sleep 1999;22:61-6.
10. Yoshioka M, Goda Y, Togashi H. Pharmacological characterization of 5-hydroxytryptamine-induced apnea in the rat. J Pharmacol Exp Ther 1992;260:917-24.
11. Jacobs L, Comroe JH. Reflex apnea, bradycardia, and hypotension produced by serotonin in cats. Circ Res 1971;29:145-55.
12. Carley DW, Radulovacki M. Role of peripheral serotonin in the regulation of central sleep apneas in rats. Chest 1999;115:1397-401.
13. 3-receptor antagonist GR 38032F suppresses sleep apneas in rats. Sleep 1998;21:131-6.
14. Fenik P, Ogawa H, Veasey SC. Hypoglossal nerve response to 5-HT3 drugs injected into the XII nucleus and vena cava in the rat. Sleep 2001;24:871-8.
15. Veasey SC, Chachkes J, Fenik P, Hendricks JC. The effects of ondansetron on sleep-disordered breathing in the English bulldog. Sleep 2001;24:155-60.
16. Carley DW, Radulovacki M. Mirtazapine, a mixed-profile serotonin agonist/antagonist, suppresses sleep apnea in the rat. Am J Respir Crit Care Med 1999;160:1824-9.
17. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999;22:667-89.
18. Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC. Quantification of sleepiness: a new approach. Psychophysiology 1973;10:431-6.
19. Rechtschaffen A, Kales A. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects Los Angeles: Brain Information Service/Brain Research Institute UCLA; 1968.
20. EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep 1992;15:173-84.
21. Okabe S, Mackiewicz M, Kubin L. Serotonin receptor mRNA expression in the hypoglossal motor nucleus. Respir Physiol 1997;110:151-60.
22. Strecker RE, Thakkar MM, Porkka-Heiskanen T, Dauphin LJ, Bjorkum AA, McCarley RW. Behavioral state-related changes of extracellular serotonin concentration in the pedunculopontine tegmental nucleus: a microdialysis study in freely moving animals. Sleep Res Online 1999;2:21-7.
23. Blanco-Centurion CA, Salin-Pascual RJ. Extracellular serotonin levels in the medullary reticular formation during normal sleep and after REM sleep deprivation. Brain Res 2001;923:128-36.
24. Lai YY, Kodama T, Siegel JM. Changes in monoamine release in the ventral horn and hypoglossal nucleus linked to pontine inhibition of muscle tone: an in vivo microdialysis study. J Neurosci 2001;21:7384-91.
25. Sood S, Raddatz E, Liu X, Liu H, Horner RL. Inhibition of serotonergic medullary raphe obscurus neurons suppresses genioglossus and diaphragm activities in anesthetized but not conscious rats. J Appl Physiol 2006;100:1807-21.
26. Veasey SC. Serotonin agonists and antagonists in obstructive sleep apnea: therapeutic potential. Am J Respir Med 2003;2:21-9.
27. Martin-Body RL, Grundy HR. Effects of neurotoxin-induced brainstem lesions on the respiratory responses of conscious rats. Clin Exp Pharmacol Physiol 1985;12:427-37.
28. Matsumoto S. Effects of carotid Body chemoreceptor stimulation by 5-HT on phrenic nerve activity and ventilation in the rabbit. Arch Int Pharmacodynam Ther 1981;254:282-92.
29. Simpson KH, Murphy P, Colthup PV, Whelan P. Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers. Psychopharmacology (Berl) 1992;109:497-8.
30. Carley D, Olopade S, Seink S, Radulovacki M. Serotonin antagonist improves obstructive sleep apnea. Sleep Med 2003;4:S6.
31. Stradling J, Smith D, Radulovacki M, Carley D. Effect of ondansetron on moderate obstructive sleep apnoea, a single night, placebo-controlled trial. J Sleep Res 2003;12:169-70.
32. Faris PL, Kim SW, Meller WH, et al. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet 2000;355:792-7.
33. Castillo JL, Menendez P, Segovia L, Guilleminault C. Effectiveness of mirtazapine in the treatment of sleep apnea/hypopnea syndrome (SAHS). Sleep Med 2004;5:507-8.
34. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770, and its enantiomers. Neuropharmacology 1988;27:399-408.
35. de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996;57:19-25.
36. DeVane CL. Differential pharmacology of newer antidepressants. J Clin Psychiatry 1998;59 Suppl 20:85-93.
37. Mendelson WB, Maczaj M, Holt J. Buspirone administration to sleep apnea patients. J Clin Psychopharmacol 1991;11:71-2.
38. Berry RB, Koch GL, Hayward LF. Low-dose mirtazapine increases genioglossus activity in the anesthetized rat. Sleep 2005;28:78-84.
39. Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001;7:249-64.
40. Behnke K, Sogaard J, Martin S, et al. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol 2003;23:358-64.
41. Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinetics 2000;38:461-74.